PTKFY:OTCMKTS
PT Kalbe Farma Unsponsored Indonesia ADR
US$ ७.९२
०.००%
(०.००) 1D
अक्टोबर २९, ०९:४१:३७ GMT-५ · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for PTKFY...
Mkt. cap
३.३५ शंख
Avg. vol.
१.९६ हजार
Volume
१८६.००
52-wk high
US$ १६.३६
52-wk low
US$ ७.२१
Beta
०.०९
Shares outstanding
२३.४१ करोड
No. of employees
१३ हजार
Mkt. cap
३.३५ शंख
Avg. vol.
१.९६ हजार
Volume
१८६.००
52-wk high
US$ १६.३६
52-wk low
US$ ७.२१
Beta
०.०९
Shares outstanding
२३.४१ करोड
No. of employees
१३ हजार
News stories
From web sources and news partners
FinancialContent
·
३० मिनेट पहिले
Leidos (NYSE:LDOS) misses Q3 2026 revenue estimates
AOL.com
·
२२ मिनेट पहिले
The S&P 500's Record Profits Are Hiding a Problem Investors Haven't Seen Before
Trefis
·
३५ मिनेट पहिले
S&P 500 Movers | Winners: IDXX, HWM, PNR | Losers: LITE, MRVL, CIEN
Yahoo Finance
·
१ घण्टा पहिले
Should iShares S&P 500 Value ETF (IVE) Be on Your Investing Radar?
Profile
PT Kalbe Farma Tbk, or simply known as Kalbe, is an Indonesian pharmaceutical, healthcare and nutrition company established in 1966. The company has expanded by strategic acquisitions of pharmaceutical companies, becoming an integrated consumer health and nutrition enterprise.
The Kalbe Group has brands in the prescription drugs, OTC drugs, energy drink and nutrition products, with a distribution arm that reaches over one million outlets. Notably, the company produces misoprostol, a drug which is used to treat stomach ulcers but is also widely used in Indonesia as an illegal abortifacient.
Company brands in healthcare and pharmaceutical segments include Promag, Mixagrip, Woods, Komix, Diabetasol, Prenagen, Extra Joss and Fitbar.
Kalbe is the largest publicly listed pharmaceutical company in Southeast Asia with around US$5 billion in market capitalization and revenues of over Rp 15 trillion. The name "Kalbe" is a syllabic abbreviation of its founder's name: Khouw Lip Boen. Wikipedia
About PT Kalbe Farma Unsponsored Indonesia ADR